Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
JP Morgan Healthcare Conference Follow-up
22
2025.01
During the JP Morgan Healthcare Conference 2025, Kangstem Biotech held one-on-one business meetings with multinational pharmaceutical companies, including leading global firms, to share updates on the development of its major pipeline and discuss commercialization strategies, such as expanding into overseas markets.
During the JP Morgan Healthcare Conference 2025, Kangstem Biotech held one-on-one business meetings with multinational pharmaceutical companies, including leading global firms, to share updates on the development of its major pipeline and discuss commercialization strategies, such as expanding into overseas markets.
The Head of Business Development at Kangstem Biotech stated, “Through this conference, we engaged in individual partnering meetings with top global pharmaceutical companies. The interest in OSCA, our osteoarthritis treatment, was particularly high. European big pharma, with whom we have been in ongoing discussions through Bio USA and Bio Europe, shared detailed feedback on key points, including the excellent results from our Phase 1 clinical trials and imaging evaluation data.”
“Business meetings are not one-time events but part of an ongoing dialogue that gradually brings us closer to a licensing agreement. We are already preparing for follow-up meetings in the future.”
Meanwhile, a leading U.S. pharmaceutical company focused on Kangstem Biotech’s skin organoids as part of its animal substitution test methods and requested an individual meeting before the conference. In particular, the company expressed strong interest in Kangstem Biotech’s technology and patents, discussing atopic dermatitis organoid models and the key elements for commercializing hair follicle organoids. After the conference, the company requested additional data on the skin and hair follicle organoid technologies and will continue specific discussions on commercialization.
Kangstem Biotech plans to develop step-by-step collaborations with the multinational pharmaceutical companies met at the conference, focusing on the osteoarthritis treatment OSCA and skin organoids. Building on this, the company aims to achieve key R&D milestones, including global technology exports and investments in OSCA and organoid technologies, to establish a stable and continuous development environment in the coming year.